LipovaxinS4-EAH not checked
PT Bio Farma · LipovaksinS4-EAH
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “0,5 mL of Middle Dose LipovaxinS4-EAH. Administered twice, 28 days apart”In the company’s words, NCT07647107 on ClinicalTrials.gov
- Tested for
- Tuberculosis, TB Infection
- Main trialPhase 1
- “A Phase I, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate Safety and Immunogenicity of Lipovaxin Tuberculosis Vaccine (Bio Farma) in Healthy Populations Aged 18-40 Years in Indonesia”In the company’s words, NCT07647107 on ClinicalTrials.gov
- Other names
- LipovaksinS4-EAH
Other drugs for Tuberculosis
- QuabodepistatOtsuka · Phase 3
- MTBVACBiofabri, S.L · Phase 3
- SudapyridineShanghai Jiatan Pharmatech Co., Ltd · Phase 3
- RBCG-N-RSVBiothervax SpA · Phase 2
- BNT164a1BioNTech · Phase 1/2
- BNT164b1BioNTech · Phase 1/2
Coming up1
- Jul 2027Phase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07647107
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jul 2027 | A Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy Populations |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026